## In the claims:

- 1 1. (Original) A solid dosage form comprising:
- 2 bupropion hydrochloride; and
- a stabilizer, wherein the stabilizer comprises glucono delta lactone or its
- 4 corresponding open chain hydroxy acid derivative.
- 1 2. (Original) The solid dosage form of claim 1, wherein the bupropion hydrochloride
- 2 retains at least 80% of the bupropion hydrochloride potency after storage for three months at
- 3 40°C and 75% relative humidity.
- 1 3. (Original) The solid dosage form of claim 1, wherein the stabilizer is glucono delta
- 2 lactone.
- 1 4. (Original) The solid dosage form of claim 1, wherein the stabilizer is a corresponding
- 2 open chain hydroxy acid derivative of glucono delta lactone.
- 1 5. (Original) The solid dosage form of claim 4, wherein the corresponding open chain
- 2 hydroxy acid derivative of glucono delta lactone is gluconic acid.
- 1 6. (Original) The solid dosage form of claim 1, wherein the concentration of glucono
- 2 delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to
- 3 about 100% by weight of the bupropion hydrochloride.
- 1 7. (Original) The solid dosage form of claim 1, wherein the concentration of glucono
- 2 delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to
- 3 about 50% by weight of the bupropion hydrochloride.
- 1 8. (Original) The solid dosage form of claim 1, wherein the amount of bupropion
- 2 hydrochloride comprises between about 25 and about 500 mg w/w of the solid dosage form.
- 1 9. (Original) The solid dosage form of claim 1, wherein the solid dosage form comprises
- 2 one or more of a tablet, a capsule, and a granulate with or without an immediate release
- 3 profile, a modified release profile, or an extended release profile.
- 1 10. (Cancelled) The solid dosage form of claim 9, wherein the solid dosage form
- 2 comprises a tablet.

- 1 11. (Cancelled) The solid dosage form of claim 10, wherein the tablet comprises a
- 2 sustained release tablet.
- 1 12. (Cancelled) The solid dosage form of claim 9, wherein the solid dosage form
- 2 comprises a capsule.
- 1 13. (Cancelled) The solid dosage form of claim 12, wherein the capsule comprises a
- 2 sustained release capsule.
- 1 14. (Cancelled) The solid dosage form of claim 1, further comprising one or more
- 2 pharmaceutically acceptable excipients comprising one or more of rate controlling polymers,
- diluents, binders, disintegrants, lubricants, glidants, and coloring agents.
- 1 15. (Cancelled) The solid dosage form of claim 14, wherein the release rate controlling
- 2 polymers comprises one or more of cellulose derivatives, acrylates, a mixture of
- 3 polyvinlyacetate and povidone, polyethylene oxides, starch and its derivatives, gums,
- 4 alginates, carbohydrate based polymers, and polysaccharide.
- 1 16. (Cancelled) The solid dosage form of claim 14, wherein the cellulose derivative
- 2 comprises one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose,
- 3 hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and sodium
- 4 carboxymethylcellulose.
- 1 17. (Cancelled) The solid dosage form of claim 16, wherein the cellulose derivative
- 2 comprises hydroxypropyl cellulose.
- 1 18. (Cancelled) The solid dosage form of claim 14, wherein the diluent comprises
- 2 microcrystalline cellulose.
- 1 19. (Cancelled) The solid dosage form of claim 14, wherein the lubricant comprises
- 2 stearic acid.
- 1 20. (Original) A process for preparing a solid dosage form of bupropion hydrochloride,
- 2 the process comprising;
- 3 mixing bupropion hydrochloride and a stabilizer to form a blend, wherein the stabilizer
- 4 comprises glucono delta lactone or its corresponding open chain hydroxy acid derivative; and

- 5 forming the blend into a solid dosage form.
- 1 21. (Original) The process of claim 20, wherein the solid dosage form retains at least 80%
- 2 of the bupropion hydrochloride potency after storage for three months at 40°C and 75%
- 3 relative humidity.
- 1 22. (Original) The process of claim 20, wherein the stabilizer is glucono delta lactone.
- 1 23. (Original) The process of claim 20, wherein the stabilizer is a corresponding open
- 2 chain hydroxy acid derivative of glucono delta lactone.
- 1 24. (Original) The process of claim 23, wherein the corresponding open chain hydroxy
- 2 acid derivative of glucono delta lactone is gluconic acid.
- ·1 25. (Original) The process of claim 20, wherein the concentration of glucono delta
- 2 lactone or corresponding open chain hydroxy derivative comprises from between about 5% to
- 3 about 100% by weight of bupropion hydrochloride.
- 1 26. (Original) The process of claim 25, wherein the concentration of glucono delta
- 2 lactone or corresponding open chain hydroxy derivative comprises from between about 5% to
- 3 about 50% by weight of bupropion hydrochloride.
- 1 27. (Original) The process of claim 20, wherein the amount of bupropion hydrochloride
- 2 comprises from between about 25 to about 500 mg w/w of the solid dosage form.
- 1 28. (Cancelled) The process of claim 20, wherein forming the blend into a solid dosage
- 2 form comprises forming a tablet, capsule or granulate with or without an immediate release
- 3 profile, a modified release profile, or an extended release profile.
- 1 29. (Cancelled) The process of claim 28, wherein the solid dosage form comprises a
- 2 tablet.
- 1 30. (Cancelled) The process of claim 29, wherein the tablet comprises a sustained release
- 2 tablet.
- 1 31. (Cancelled) The process of claim 28, wherein the solid dosage form comprises a
- 2 capsule.

- 1 32. (Cancelled) The process of claim 31, wherein the capsule comprises a sustained
- 2 release capsule.
- 1 33. (Cancelled) The process of claim 20, wherein the mixing comprises wet granulation.
- 1 34. (Cancelled) The process of claim 20, wherein the mixing comprises dry granulation.
- 1 35. (Cancelled) The process of claim 20, wherein the mixing comprises direct
- 2 compression.
- 1 36. (Original) The process of claim 20, wherein the solid dosage form further comprises
- 2 one or more pharmaceutically acceptable excipients selected from rate controlling polymers,
- diluents, binders, disintegrants, lubricants, glidants and coloring agents.
- 1 37. (Cancelled) The process of claim 36, wherein the release rate controlling polymer
- 2 comprises one or more of cellulose derivatives, acrylates, a mixture of polyvinlyacetate and
- 3 povidone, polyethylene oxides, starch and their derivatives, gums, alginates, carbohydrate
- 4 based polymers, and polysaccharide.
- 1 38. (Cancelled) The process of claim 37, wherein the cellulose derivative comprises one
- 2 or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose,
- 3 hydroxypropylcellulose, hydroxypropyl methylcellulose, and sodium
- 4 carboxymethylcellulose.
- 1 39. (Cancelled) The process of claim 38, wherein the cellulose derivative comprises
- 2 hydroxypropyl cellulose.
- 1 40. (Cancelled) The process of claim 36, wherein the diluent comprises microcrystalline
- 2 cellulose.
- 1 41. (Cancelled) The process of claim 36, wherein the lubricant comprises stearic acid.
- 1 42. (Original) A method of treating either or both of depression and nicotine addiction in
- 2 a human, the method comprising orally administering to a human in need thereof a solid
- 3 dosage form comprising bupropion hydrochloride and a stabilizer, wherein the stabilizer
- 4 comprises glucono delta lactone or its corresponding open chain hydroxy acid derivative.

- 1 43. (Cancelled) The method of claim 42, wherein the bupropion hydrochloride retains at
- 2 least 80% of the bupropion hydrochloride potency after storage for three months at 40°C and
- 3 75% relative humidity.
- 1 44. (Original) The method of claim 42, wherein the stabilizer is glucono delta lactone.
- 1 45. (Original) The method of claim 42, wherein the stabilizer is a corresponding open
- 2 chain hydroxy acid derivative of glucono delta lactone.
- 1 46. (Cancelled) The method of claim 45, wherein the corresponding open chain hydroxy
- 2 acid derivative of glucono delta lactone is gluconic acid.
- 1 47. (Cancelled) The method of claim 42, wherein the concentration of glucono delta
- 2 lactone or corresponding open chain hydroxy derivative comprises from about 5% to about
- 3 100% by weight of the bupropion hydrochloride.
- 1 48. (Cancelled) The method of claim 42, wherein the concentration of glucono delta
- 2 lactone or corresponding open chain hydroxy derivative comprises from about 5% to about
- 3 50% by weight of the bupropion hydrochloride.
- 1 49. (Original) The method of claim 42, wherein the amount of bupropion hydrochloride
- 2 comprises between about 25 and about 500 mg w/w of the solid dosage form.
- 1 50. (Cancelled) The method of claim 42, wherein the solid dosage form comprises one or
- 2 more of a tablet, a capsule, and a granulate with or without an immediate release profile, a
- 3 modified release profile, or an extended release profile.